dm+d

Unassigned

New Medicines

Early to mid stage Huntington's disease - first-line

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Apr 21Removed from planned filings; development discontinued [17].
Mar 21Roche announces that it will discontinue dosing in the PIII GENERATION study. This decision was based on results of a pre-planned review of the data conducted by an unblinded Independent Data Monitoring Committee [16].

Category

Antisense oligonucleotide targeting the huntingtin protein, the mutant form of which is neurotoxic
UK prevalence according to GP records has increased from about 5 per 100,000 in 1990 to around 12 per 100,000 in 2010, however incidence has remained constant at about 7 per million person-years: it is thought that this is due to greater willingness to record the diagnosis by GPs, and improved survival [3].
Early to mid stage Huntington's disease - first-line
Intrathecal